CORE--CLINICAL LABORATORY CORE

行政和临床化学核心的目的是为该项目提供全面的日常行政指导，并为在该计划项目拨款的保护伞下提出的无数生化分析提供实验室支持。通过在核心实验室环境中进行这些测定，我们将以符合成本效益的方式利用这项提议所需的用品和实验室人员。更重要的是，它将确保对这些分析性能的质量控制，并将执行各自测试方案的几个实验室之间可能出现的潜在差异降至最低。所有的尿液分析将在矿物代谢实验室进行，这是CLIA批准的实验室。所有程序都是标准化的，并包括适当的质量控制样本 每跑一次。将在本实验室中进行的分析将为每种成分提供 第一、第二、第四和第五部分将要求进行24小时尿液分析以确定结石风险 参数。类似的测试也将在禁食2小时的样本上完成，作为 组分一和二。可滴定酸将是组分二的主要需要，次要部分是 第四部分：血清分析需要同时使用酶联免疫吸附试验和放射性同位素方法。这些分析将在Zerwekh博士的指导下在RIA实验室进行。除维生素D代谢物分析外，所有拟议的测试都是使用市面上可获得的试剂盒进行的，目前该实验室采用的是测试方法。第三部分将要求对大鼠的尿液和血浆进行有限的电解质评估。针对成分II的三种分析方法，即血清胰岛素、游离脂肪酸和乳酸，将在成分II的共同研究员尼古拉·阿巴特博士的实验室进行。

The purpose of the administrative and clinical chemistry core is to provide overall daily administrative guidance for the project and laboratory support for the myriad of biochemical analyses proposed under the umbrella of this program project grant. By performing these determinations in a core laboratory setting, we will attain cost-effective utilization of the supplies and laboratory personnel required for this proposal. More importantly, it will insure quality control over the performance of these analyses and minimize the potential variation that might occur between several laboratories performing their own testing protocols. All of the urinary analyses will be performed in the Mineral Metabolism laboratory, a CLIA-approved laboratory. The procedures are all standardized and appropriate quality control specimens are included with each run. The analyses to be performed in this laboratory will subserve each component as specified in Table A. Components I, II, IV, and V will require 24-hour urine analyses for stone-risk parameters. Similar testing will also be accomplished on 2-hour fasting specimens as part of Components I and II. Titratable acidities will be a major need for component II and a minor part of component IV. Serum assays will require the use of both ELISA and radioisotopic methods. These assays will be performed in the RIA laboratory under the direction of Dr. Zerwekh. Except for the vitamin D metabolite analyses, all of the proposed tests are performed with commercially available kits and are currently employed assays in this laboratory. Component III will require a limited electrolyte assessment on rat urine and plasma. Three of the assays specific to component II, namely serum insulin, free fatty acid, and lactate will be performed in the laboratory of Dr. Nicola Abate, co-investigator for Component II.